Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies-Reference-Cited by-同舟云学术

Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies

Published:2014-06-13 Issue:10 Volume:21 Page:761-766
ISSN:1868-6974
Container-title:Journal of Hepato-Biliary-Pancreatic Sciences
language:en
Short-container-title:J Hepatobiliary Pancreat Sci

Author:

Yanagimoto Hiroaki¹,Ishii Hiroshi²,Nakai Yousuke³,Ozaka Masato²,Ikari Takaaki²,Koike Kazuhiko³,Ueno Hideki⁴,Ioka Tatsuya⁵,Satoi Sohei¹,Sho Masayuki⁶,Okusaka Takuji⁴,Tanaka Masao⁷,Shimokawa Toshio⁸,Kwon A-Hon¹,Isayama Hiroyuki³

Affiliation:

1. Department of Surgery; Kansai Medical University; 2-5-1 Shin-machi Hirakata 573-1010 Japan

2. Department of Gastroenterology; Cancer Institute Hospital; Tokyo Japan

3. Department of Gastroenterology; The University of Tokyo; Tokyo Japan

4. Hepatobiliary and Pancreatic Oncology Division; National Cancer Center Hospital; Tokyo Japan

5. Department of Screening for Cancers of Digestive Organs; Osaka Medical Center for Cancer and Cardiovascular Diseases; Osaka Japan

6. Department of Surgery; Nara Medical University; Kashihara Japan

7. Department of Surgery and Oncology, Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

8. Graduate School of Medicine and Engineering; University of Yamanashi; Kofu Japan

Publisher

Wiley

Subject

Hepatology,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jhbp.130/fullpdf

Reference27 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

4. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

5. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of neoadjuvant gemcitabine plus S‐1 and radiation therapy for borderline resectable pancreatic cancer;Journal of Hepato-Biliary-Pancreatic Sciences;2022-11-21

2. A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer;Surgical Case Reports;2022-10-07

3. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma;Scientific Reports;2022-06-15

4. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan;JAMA Network Open;2022-01-31

5. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2021-04